News

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Dec 7, 2022
2022
Press Release Regulatory

Elicera Therapeutics reports additional signals of clinical activity in patients treated for neuroendocrine tumors in the ELC-100 study at the Oncolytic Virotherapy Summit in Boston

Regulatory Press Release
Read more
Nov 18, 2022
2022
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2022

Regulatory Press Release
Read more
Nov 16, 2022
2022
Press Release Non-regulatory

Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research

Non-regulatory Press Release
Read more
Nov 3, 2022
2022
Press Release Regulatory

Nomination Committee for Elicera Therapeutics appointed

Regulatory Press Release
Read more
Oct 18, 2022
2022
Press Release Non-regulatory

Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution

Non-regulatory Press Release
Read more
Oct 12, 2022
2022
Press Release Non-regulatory

Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy

Non-regulatory Press Release
Read more
Sep 7, 2022
2022
News

LifeScientist interviews Di Yu

News
Read more
Aug 31, 2022
2022
News

Oncology in Sweden publishes an article by Magnus Essand on Elicera's iTANK platform and upcoming clinical study

News
Read more
Aug 22, 2022
2022
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022

Regulatory Press Release
Read more
Aug 12, 2022
2022
Press Release Non-regulatory

Elicera Therapeutics announces participation in several industry and partnering conferences

Non-regulatory Press Release
Read more
Jun 2, 2022
2022
Press Release Regulatory

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory Press Release
Read more
Apr 27, 2022
2022
Press Release Non-regulatory

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Non-regulatory Press Release
Read more
Apr 27, 2022
2022
News

Interviews with Magnus Essand and Gunilla Enblad at SWECARNET's education day April 27

News
Read more
Apr 26, 2022
2022
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory Press Release
Read more
Apr 10, 2022
2022
News

Upsala Nya Tidning writes about Elicera's research and upcoming clinical studies

News
Read more
Apr 7, 2022
2022
News

Nordic Life Science News writes about the iTANK-publication

News
Read more
Apr 6, 2022
2022
News

Biostock makes a video interview with CSO, professor Magnus Essand, on the iTANK, publication.

News
Read more
Apr 4, 2022
2022
Press Release Regulatory

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory Press Release
Read more
Mar 1, 2022
2022
News

Elicera featured in Life Science Sweden's perspective on CAR T-cell therapies

News
Read more
Feb 24, 2022
2022
Press Release Non-regulatory

Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022

Non-regulatory Press Release
Read more

Sign up for Press Releases

By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.